Magnus Financial Group LLC purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 844 shares of the medical research company’s stock, valued at approximately $258,000.

A number of other large investors also recently made changes to their positions in BIO. BlackRock Inc. increased its position in shares of Bio-Rad Laboratories by 3.6% during the fourth quarter. BlackRock Inc. now owns 1,936,008 shares of the medical research company’s stock worth $449,580,000 after purchasing an additional 68,124 shares in the last quarter. Vanguard Group Inc increased its position in shares of Bio-Rad Laboratories by 2.0% during the third quarter. Vanguard Group Inc now owns 1,832,968 shares of the medical research company’s stock worth $573,701,000 after purchasing an additional 35,261 shares in the last quarter. Levin Capital Strategies L.P. increased its position in shares of Bio-Rad Laboratories by 7,126.2% during the fourth quarter. Levin Capital Strategies L.P. now owns 569,205 shares of the medical research company’s stock worth $132,181,000 after purchasing an additional 561,328 shares in the last quarter. Millennium Management LLC increased its position in shares of Bio-Rad Laboratories by 5.4% during the fourth quarter. Millennium Management LLC now owns 398,328 shares of the medical research company’s stock worth $92,500,000 after purchasing an additional 20,503 shares in the last quarter. Finally, Westfield Capital Management Co. LP increased its position in shares of Bio-Rad Laboratories by 8.4% during the fourth quarter. Westfield Capital Management Co. LP now owns 376,018 shares of the medical research company’s stock worth $87,319,000 after purchasing an additional 29,265 shares in the last quarter. 62.67% of the stock is owned by institutional investors.

In related news, EVP Timothy S. Ernst sold 345 shares of the stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $290.00, for a total transaction of $100,050.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 27.84% of the stock is currently owned by corporate insiders.

Shares of NYSE BIO traded down $0.59 during mid-day trading on Friday, reaching $293.37. 89,369 shares of the company’s stock were exchanged, compared to its average volume of 240,976. The stock has a market cap of $8.74 billion, a PE ratio of 50.23, a P/E/G ratio of 2.74 and a beta of 1.23. The company has a current ratio of 4.57, a quick ratio of 3.24 and a debt-to-equity ratio of 0.13. Bio-Rad Laboratories, Inc. has a 52-week low of $220.05 and a 52-week high of $345.15.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Wednesday, May 8th. The medical research company reported $1.65 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.53. The business had revenue of $553.98 million during the quarter, compared to analysts’ expectations of $548.82 million. Bio-Rad Laboratories had a return on equity of 4.15% and a net margin of 24.84%. Research analysts predict that Bio-Rad Laboratories, Inc. will post 7.15 EPS for the current year.

Several analysts have issued reports on BIO shares. Deutsche Bank upped their target price on Bio-Rad Laboratories from $330.00 to $350.00 and gave the company a “buy” rating in a report on Friday, March 1st. ValuEngine upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, May 9th. Zacks Investment Research cut Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, Barclays upped their target price on Bio-Rad Laboratories from $340.00 to $350.00 and gave the company an “overweight” rating in a report on Thursday, May 9th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Bio-Rad Laboratories has an average rating of “Buy” and an average target price of $365.00.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.dailypolitical.com/2019/05/25/844-shares-in-bio-rad-laboratories-inc-bio-purchased-by-magnus-financial-group-llc.html.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Read More: Fundamental Analysis

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.